Advances in magnetic resonance (2006)

Investigative Radiology

Volumn 41, Issue 12, 2006, Pages 904-909

  Runge, Val M ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Contrast media; Magnetic resonance

Indexed keywords

CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SYSTEM; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOFREQUENCY; REVIEW; SIGNAL NOISE RATIO; UROGENITAL SYSTEM;

EID: 33751005029     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000250461.03245.5c     Document Type: Review

References (104)

1. Runge VM. Advances in magnetic resonance. Invest Radiol. 2005;40:798-802.
2. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005;40:743-753.
3. Runge VM, Patel MC, Baumann SS, et al. T1-weighted imaging of the brain at 3 tesla using a 2-dimensional spoiled gradient echo technique. Invest Radiol. 2006;41:68-75.
4. Runge VM, Case RS, Sonnier HL. Advances in clinical 3-tesla neuroimaging. Invest Radiol. 2006;41:63-67.
5. Wintersperger BJ, Runge VM, Biswas J, et al. Brain magnetic resonance imaging at 3 tesla using BLADE compared with standard rectilinear data sampling. Invest Radiol. 2006;41:586-592.
6. Deng J, Miller FH, Salem R, et al. Multishot diffusion-weighted PROPELLER magnetic resonance imaging of the abdomen. Invest Radiol. 2006;41:769-775.
7. Fink C, Ley S, Kroeker R, et al. Time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the chest: combination of parallel imaging with view sharing (TREAT). Invest Radiol. 2005;40:40-48.
8. Mandry D, Pedersen M, Odille F, et al. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in Sprague-Dawley rats. Invest Radiol. 2005;40:295-305.
9. Paetzel C, Zorger N, Bachthaler M, et al. Magnetic resonance-guided percutaneous angioplasty of femoral and popliteal artery stenoses using real-time imaging and intra-arterial contrast-enhanced magnetic resonance angiography. Invest Radiol. 2005;40:257-262.
10. de Vries M, de Koning PJ, de Haan MW, et al. Accuracy of semiautomated analysis of 3D contrast-enhanced magnetic resonance angiography for detection and quantification of aortoiliac stenoses. Invest Radiol. 2005;40:495-503.
11. Zheng J, Li D, Maggioni F, et al. Single-session magnetic resonance coronary angiography and myocardial perfusion imaging using the new blood pool compound B-22956 (gadocoletic acid): initial experience in a porcine model of coronary artery disease. Invest Radiol. 2005;40:604-613.
12. Port M, Corot C, Violas X, et al. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005;40:565-573.
13. Zhang L, Chapman BE, Parker DL, et al. Automatic detection of three-dimensional vascular tree centerlines and bifurcations in high-resolution magnetic resonance angiography. Invest Radiol. 2005;40:661-671.
14. Kramer U, Nael K, Laub G, et al. High-resolution magnetic resonance angiography of the renal arteries using parallel imaging acquisition techniques at 3.0 T: initial experience. Invest Radiol. 2006;41:125-132.
15. Nael K, Michaely HJ, Villablanca P, et al. Time-resolved contrast enhanced magnetic resonance angiography of the head and neck at 3.0 tesla: initial results. Invest Radiol. 2006;41:116-124.
16. Cury RC, Houser SL, Furie KL, et al. Vulnerable plaque detection by 3.0 tesla magnetic resonance imaging. Invest Radiol. 2006;41:112-115.
17. Bachmann R, Nassenstein I, Kooijman H, et al. Spontaneous acute dissection of the internal carotid artery: high-resolution magnetic resonance imaging at 3.0 tesla with a dedicated surface coil. Invest Radiol. 2006;41:105-111.
18. Allkemper T, Heindel W, Kooijman H, et al. Effect of field strengths on magnetic resonance angiography: comparison of an ultrasmall super-paramagnetic iron oxide blood-pool contrast agent and gadopentetate dimeglumine in rabbits at 1.5 and 3.0 tesla. Invest Radiol. 2006;41:97-104.
19. Koktzoglou I, Harris KR, Tang R, et al. Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest Radiol. 2006;41:299-304.
20. Deshpande VS, Cavagna F, Maggioni F, et al. Comparison of gradient-echo and steady-state free precession for coronary artery magnetic resonance angiography using a gadolinium-based intravascular contrast agent. Invest Radiol. 2006;41:292-298.
21. de Haen C, Anelli PL, Lorusso V, et al. Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. Invest Radiol. 2006;41:279-291.
22. Nael K, Ruehm SG, Michaely HJ, et al. High spatial-resolution CEMRA of the carotid circulation with parallel imaging: comparison of image quality between 2 different acceleration factors at 3.0 tesla. Invest Radiol. 2006;41:391-399.
23. Steger-Hartmann T, Graham PB, Muller S, et al. Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol. 2006;41:449-459.
24. Fenchel M, Nael K, Ruehm S, et al. Isotropic high spatial resolution magnetic resonance angiography of the supra-aortic arteries using two-dimensional parallel imaging (iPAT2) at 3 tesla: a feasibility study. Invest Radiol. 2006;41:545-552.
25. Yang CW, Carr JC, Francois CJ, et al. Coronary magnetic resonance angiography using magnetization-prepared contrast-enhanced breath-hold volume-targeted imaging (MPCE-VCATS). Invest Radiol. 2006;41:639-644.
26. Fenchel M, Nael K, Deshpande VS, et al. Renal magnetic resonance angiography at 3.0 tesla using a 32-element phased-array coil system and parallel imaging in 2 directions. Invest Radiol. 2006;41:697-703.
27. Nael K, Fenchel M, Salamon N, et al. Three-dimensional cerebral contrast-enhanced magnetic resonance venography at 3.0 tesla: initial results using highly accelerated parallel acquisition. Invest Radiol. 2006;41:763-768.
28. Villablanca JP, Habibi R, Michaely HJ, et al. 3T contrast-enhanced MR angiography for evaluation of the intracranial arteries: comparison with time-of-flight MR angiography and multi-slice CT angiography. Invest Radiol. 2006;41:799-805.
29. Yang DH, Kim TH, Choi JW, et al. Manganese dipyridoxyl diphosphate (MnDPDP)-enhanced magnetic resonance imaging of acute reperfused myocardial injury in a cat model: part II: comparison with cine magnetic resonance imaging. Invest Radiol. 2005;40:56-61.
30. Kim TH, Yang DH, Choi JW, et al. Manganese dipyridoxyl diphosphate (MnDPDP)-enhanced magnetic resonance imaging of acute reperfused myocardial injury in a cat model: part I: comparison with pathologic examination. Invest Radiol. 2005;40:49-55.
31. Haage P, Karaagac S, Spuntrup E, et al. Feasibility of pulmonary ventilation visualization with aerosolized magnetic resonance contrast media. Invest Radiol. 2005;40:85-88.
32. Fink C, Ley S, Risse F, et al. Effect of inspiratory and expiratory breathhold on pulmonary perfusion: assessment by pulmonary perfusion magnetic resonance imaging. Invest Radiol. 2005;40:72-79.
33. Plathow C, Schoebinger M, Fink C, et al. Evaluation of lung volumetry using dynamic three-dimensional magnetic resonance imaging. Invest Radiol. 2005;40:173-179.
34. Bruvold M, Nordhoy W, Anthonsen HW, et al. Manganese-calcium interactions with contrast media for cardiac magnetic resonance imaging: a study of manganese chloride supplemented with calcium gluconate in isolated Guinea pig hearts. Invest Radiol. 2005;40:117-125.
35. Uzumcu M, van der Geest RJ, Sonka M, et al. Multiview active appearance models for simultaneous segmentation of cardiac 2- and 4-chamber long-axis magnetic resonance images. Invest Radiol. 2005;40:195-203.
36. Penno E, Johnsson C, Johansson L, et al. Comparison of ultrasmall superparamagnetic iron oxide particles and low molecular weight contrast agents to detect rejecting transplanted hearts with magnetic resonance imaging. Invest Radiol. 2005;40:648-654.
37. Buecker A, Katoh M, Krombach GA, et al. A feasibility study of contrast enhancement of acute myocardial infarction in multislice computed tomography: comparison with magnetic resonance imaging and gross morphology in pigs. Invest Radiol. 2005;40:700-704.
38. Maskali F, Ayalew A, Marie PY, et al. Changes in first-pass interstitial kinetics of DTPA in myocardium submitted to low-flow ischemia. Invest Radiol. 2005;40:766-772.
39. Uzumcu M, van der Geest RJ, Swingen C, et al. Time continuous tracking and segmentation of cardiovascular magnetic resonance images using multidimensional dynamic programming. Invest Radiol. 2006;41:52-62.
40. Gutberlet M, Noeske R, Schwinge K, et al. Comprehensive cardiac magnetic resonance imaging at 3.0 tesla: feasibility and implications for clinical applications. Invest Radiol. 2006;41:154-167.
41. Huber A, Bauner K, Wintersperger BJ, et al. Phase-sensitive inversion recovery (PSIR) single-shot TrueFISP for assessment of myocardial infarction at 3 tesla. Invest Radiol. 2006;41:148-153.
42. Wintersperger BJ, Bauner K, Reeder SB, et al. Cardiac steady-state free precession CINE magnetic resonance imaging at 3.0 tesla: impact of parallel imaging acceleration on volumetric accuracy and signal parameters. Invest Radiol. 2006;41:141-147.
43. Michaely HJ, Nael K, Schoenberg SO, et al. Analysis of cardiac function - comparison between 1.5 Tesla and 3.0 Tesla cardiac cine magnetic resonance imaging: preliminary experience. Invest Radiol. 2006;41:133-140.
44. Molinari F, Gaudino S, Fink C, et al. Simultaneous cardiac and respiratory synchronization in oxygen-enhanced magnetic resonance imaging of the lung using a pneumotachograph for respiratory monitoring. Invest Radiol. 2006;41:476-485.
45. Plathow C, Klopp M, Schoebinger M, et al. Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry. Invest Radiol. 2006;41:443-448.
46. Molinari F, Fink C, Risse F, et al. Assessment of differential pulmonary blood flow using perfusion magnetic resonance imaging: comparison with radionuclide perfusion scintigraphy. Invest Radiol. 2006;41:624-630.
47. Klumpp B, Fenchel M, Hoevelborn T, et al. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol. 2006;41:661-667.
48. Yoo SS, Park HJ, Soul JS, et al. In vivo visualization of white matter fiber tracts of preterm- and term-infant brains with diffusion tensor magnetic resonance imaging. Invest Radiol. 2005;40:110-115.
49. Schlemmer HP, Schafer J, Pfannenberg C, et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol. 2005;40:64-71.
50. Kim HJ, Pyeun YS, Kim YW, et al. A model for research on the blood-brain barrier disruption induced by unsaturated fatty acid emulsion. Invest Radiol. 2005;40:270-276.
51. Yang M, Christoforidis GA, Figueredo T, et al. Dosage determination of ultrasmall particles of iron oxide for the delineation of microvasculature in the Wistar rat brain. Invest Radiol. 2005;40:655-660.
52. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 tesla. Invest Radiol. 2005;40:792-797.
53. Kovacs S, Peeters R, Smits M, et al. Activation of cortical and subcortical auditory structures at 3 T by means of a functional magnetic resonance imaging paradigm suitable for clinical use. Invest Radiol. 2006;41:87-96.
54. Nielsen K, Rostrup E, Frederiksen JL, et al. Magnetic resonance imaging at 3.0 tesla detects more lesions in acute optic neuritis than at 1.5 tesla. Invest Radiol. 2006;41:76-82.
55. Essig M, Lodemann KP, Le-Huu M, et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol. 2006;41:256-263.
56. Noebauer-Huhmann IM, Pinker K, Barth M, et al. Contrast-enhanced, high-resolution, susceptibility-weighted magnetic resonance imaging of the brain: dose-dependent optimization at 3 tesla and 1.5 tesla in healthy volunteers. Invest Radiol. 2006;41:249-255.
57. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248.
58. Diergarten T, Martirosian P, Kottke R, et al. Functional characterization of prostate cancer by integrated magnetic resonance imaging and oxygenation changes during carbogen breathing. Invest Radiol. 2005;40:102-109.
59. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol. 2006;41:185-188.
60. Tumkur S, Vu A, Li L, et al. Evaluation of intrarenal oxygenation at 3.0 T using 3-dimensional multiple gradient-recalled echo sequence. Invest Radiol. 2006;41:181-184.
61. Jia G, Baudendistel KT, von Tengg-Kobligk H, et al. Assessing prostate volume by magnetic resonance imaging: a comparison of different measurement approaches for organ volume analysis. Invest Radiol. 2005;40:243-248.
62. Boss A, Clasen S, Kuczyk M, et al. Magnetic resonance-guided percutaneous radiofrequency ablation of renal cell carcinomas: a pilot clinical study. Invest Radiol. 2005;40:583-590.
63. Scheibl K, Schreyer AG, Kullmann F, et al. Magnetic resonance imaging gastrography: evaluation of the dark lumen technique compared with conventional gastroscopy in patients with malignant gastric disease. Invest Radiol. 2005;40:164-172.
64. Planchamp C, Montet X, Frossard JL, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol. 2005;40:187-194.
65. Tsuda N, Tsuji T, Kato N. Interstitial magnetic resonance lymphography using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid in rabbits with lymph node metastasis. Invest Radiol. 2005;40:306-312.
66. Preda A, Turetschek K, Daldrup H, et al. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol. 2005;40:349-354.
67. Pediconi F, Catalano C, Venditti F, et al. Color-coded automated signal intensity curves for detection and characterization of breast lesions: preliminary evaluation of a new software package for integrated magnetic resonance-based breast imaging. Invest Radiol. 2005;40:448-457.
68. Lucht RE, Delorme S, Hei J, et al. Classification of signal-time curves obtained by dynamic magnetic resonance mammography: statistical comparison of quantitative methods. Invest Radiol. 2005;40:442-447.
69. van den Bosch MA, Daniel BL, Mariano MN, et al. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Invest Radiol. 2005;40:436-441.
70. Marzola P, Ramponi S, Nicolato E, et al. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Invest Radiol. 2005;40:421-429.
71. Joe BN, Chen VY, Salibi N, et al. Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Invest Radiol. 2005;40:405-411.
72. Comte A, Lalande A, Cochet A, et al. Automatic fuzzy classification of the washout curves from magnetic resonance first-pass perfusion imaging after myocardial infarction. Invest Radiol. 2005;40:545-555.
73. Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol. 2005;40:526-535.
74. Lowe A, Balzer T, Hirt U. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol. 2005;40:521-525.
75. Sun R, Dittrich J, Le-Huu M, et al. Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison. Invest Radiol. 2005;40:504-513.
76. Herrmann KA, Zech CJ, Michaely HJ, et al. Comprehensive magnetic resonance imaging of the small and large bowel using intraluminal dual contrast technique with iron oxide solution and water in magnetic resonance enteroclysis. Invest Radiol. 2005;40:621-629.
77. Segers J, Le Duc G, Laumonier C, et al. Evaluation of Gd-EOB-DTPA uptake in a perfused and isolated mouse liver model: correlation between magnetic resonance imaging and monochromatic quantitative computed tomography. Invest Radiol. 2005;40:574-582.
78. Tsuda N, Tsuji T, Kato N, et al. Potential of superparamagnetic iron oxide in the differential diagnosis of metastasis and inflammation in bone marrow: experimental study. Invest Radiol. 2005;40:676-681.
79. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
80. Planchamp C, Pastor CM, Balant L, et al. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Invest Radiol. 2005;40:705-714.
81. Kalber TL, Smith CJ, Howe FA, et al. A longitudinal study of R2* and R2 magnetic resonance imaging relaxation rate measurements in murine liver after a single administration of 3 different iron oxide-based contrast agents. Invest Radiol. 2005;40:784-791.
82. Simon GH, von Vopelius-Feldt J, Fu Y, et al. Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol. 2006;41:45-51.
83. Kimelman T, Vu A, Storey P, et al. Three-dimensional T1 mapping for dGEMRIC at 3.0 T using the Look Locker method. Invest Radiol. 2006;41:198-203.
84. Chang JM, Lee JM, Lee MW, et al. Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol. 2006;41:168-174.
85. Zheng J, Perkins G, Kirilova A, et al. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol. 2006;41:339-348.
86. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol. 2006;41:332-338.
87. Preda A, van Vliet M, Krestin GP, et al. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol. 2006;41:325-331.
88. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;41:313-324.
89. Caruthers SD, Neubauer AM, Hockett FD, et al. In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 tesla. Invest Radiol. 2006;41:305-312.
90. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272-278.
91. Wersebe A, Wiskirchen J, Decker U, et al. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Invest Radiol. 2006;41:264-271.
92. Eldredge HB, Spiller M, Chasse JM, et al. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol. 2006;41:229-243.
93. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
94. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221.
95. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41:206-212.
96. Carme S, Mai W, Mazzadi A, et al. Importance of parametric mapping and deconvolution in analyzing magnetic resonance myocardial perfusion images. Invest Radiol. 2006;41:374-383.
97. Heilmann M, Kiessling F, Enderlin M, et al. Determination of pharmacokinetic parameters in DCE MRI: Consequence of nonlinearity between contrast agent concentration and signal intensity. Invest Radiol. 2006;41:536-543.
98. Dudeck O, Bogusiewicz K, Pinkernelle J, et al. Local arterial infusion of superparamagnetic iron oxide particles in hepatocellular carcinoma: a feasibility and 3.0 T MRI study. Invest Radiol. 2006;41:527-535.
99. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol. 2006;41:500-509.
100. Knopp MV, Balzer T, Esser M, et al. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol. 2006;41:491-499.
101. Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006;41:618-623.
102. Tang JS, Choy G, Bernardo M, et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol. 2006;41:691-696.
103. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofos-veset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol. 2006;41:822-830.
104. Raatschen HJ, Fu Y, Shames DM, et al. MRI enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations. Invest Radiol. 2006;41:860-867.